Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 200

1.

Highly active antiretroviral treatment containing efavirenz or nevirapine and related toxicity in the TREAT Asia HIV Observational Database.

Zhou J, Phanupak P, Kiertiburanakul S, Ditangco R, Kamarulzaman A, Pujary S; TREAT Asia HIV Observational Database.

J Acquir Immune Defic Syndr. 2006 Dec 1;43(4):501-3. No abstract available.

PMID:
17099317
[PubMed - indexed for MEDLINE]
2.

Is there cross-toxicity between nevirapine and efavirenz in subjects developing rash?

Soriano V, Dona C, Barreiro P, González-Lahoz J.

AIDS. 2000 Jul 28;14(11):1672-3. No abstract available.

PMID:
10983663
[PubMed - indexed for MEDLINE]
3.

Toxicity of non-nucleoside analogue reverse transcriptase inhibitors.

Kontorinis N, Dieterich DT.

Semin Liver Dis. 2003 May;23(2):173-82. Review.

PMID:
12800070
[PubMed - indexed for MEDLINE]
4.

[The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].

van Leth F, Lange JM.

Ned Tijdschr Geneeskd. 2006 Aug 5;150(31):1719-22. Review. Dutch.

PMID:
16924943
[PubMed - indexed for MEDLINE]
5.

NNRTI hepatotoxicity: efavirenz versus nevirapine.

Pulido F, Torralba M.

J HIV Ther. 2002 Nov;7 Suppl 2:S3-16. Review. English, Spanish. No abstract available.

PMID:
12735215
[PubMed - indexed for MEDLINE]
6.

Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients.

Ena J, Amador C, Benito C, Fenoll V, Pasquau F.

Int J STD AIDS. 2003 Nov;14(11):776-81.

PMID:
14624743
[PubMed - indexed for MEDLINE]
7.
8.

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.

Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD.

Hepatology. 2002 Jan;35(1):182-9.

PMID:
11786975
[PubMed - indexed for MEDLINE]
9.

An extremely different dysmetabolic profile between the two available nonnucleoside reverse transcriptase inhibitors: efavirenz and nevirapine.

Manfredi R, Calza L, Chiodo F.

J Acquir Immune Defic Syndr. 2005 Feb 1;38(2):236-8. No abstract available.

PMID:
15671811
[PubMed - indexed for MEDLINE]
10.

Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring?

Dahri K, Ensom MH.

Clin Pharmacokinet. 2007;46(2):109-32. Review.

PMID:
17253884
[PubMed - indexed for MEDLINE]
11.

Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.

Aranzabal L, Casado JL, Moya J, Quereda C, Diz S, Moreno A, Moreno L, Antela A, Perez-Elias MJ, Dronda F, Marín A, Hernandez-Ranz F, Moreno A, Moreno S.

Clin Infect Dis. 2005 Feb 15;40(4):588-93. Epub 2005 Jan 21.

PMID:
15712082
[PubMed - indexed for MEDLINE]
Free Article
12.

[Efavirenz--comprehensive status of studies].

[No authors listed]

MMW Fortschr Med. 2005 Apr 25;147 Spec No 1:79-81. German. No abstract available.

PMID:
16385886
[PubMed - indexed for MEDLINE]
13.

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.

van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, Cahn P, Lalloo UG, van der Westhuizen IP, Malan DR, Johnson MA, Santos BR, Mulcahy F, Wood R, Levi GC, Reboredo G, Squires K, Cassetti I, Petit D, Raffi F, Katlama C, Murphy RL, Horban A, Dam JP, Hassink E, van Leeuwen R, Robinson P, Wit FW, Lange JM; 2NN Study team.

Lancet. 2004 Apr 17;363(9417):1253-63.

PMID:
15094269
[PubMed - indexed for MEDLINE]
14.

Incidence and risk factors of rash associated with efavirenz in HIV-infected patients with preceding nevirapine-associated rash.

Manosuthi W, Thongyen S, Chumpathat N, Muangchana K, Sungkanuparph S.

HIV Med. 2006 Sep;7(6):378-82.

PMID:
16903982
[PubMed - indexed for MEDLINE]
15.

Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study.

Manfredi R, Calza L, Chiodo F.

J Acquir Immune Defic Syndr. 2004 Apr 15;35(5):492-502.

PMID:
15021314
[PubMed - indexed for MEDLINE]
16.

Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.

Chiesa E, Bini T, Adorni F, Capetti A, Rizzardini G, Faggion I, Mussini C, Sollima S, Melzi S, Bongiovanni M, Tordato F, Cicconi P, Castelnuovo B, Rusconi S, d'Arminio Monforte A.

Antivir Ther. 2003 Feb;8(1):27-35.

PMID:
12713061
[PubMed - indexed for MEDLINE]
17.

Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection.

Jordan WC, Jefferson R, Yemofio F, Tolbert L, Conlon V, Carroll H, Green DC, Green A, Green R.

J Natl Med Assoc. 2003 Dec;95(12):1152-7.

PMID:
14717471
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

[Antiretroviral-induced toxiderma in HIV-infected patients].

Caumes E, Bossi P, Katlama C, Bricaire F.

Presse Med. 2003 Sep 6;32(28):1325-33. Review. French.

PMID:
14506444
[PubMed - indexed for MEDLINE]
19.

Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity.

Ritchie MD, Haas DW, Motsinger AA, Donahue JP, Erdem H, Raffanti S, Rebeiro P, George AL, Kim RB, Haines JL, Sterling TR.

Clin Infect Dis. 2006 Sep 15;43(6):779-82. Epub 2006 Aug 15.

PMID:
16912956
[PubMed - indexed for MEDLINE]
Free Article
20.

Issues in antiretroviral toxicity.

Boyle BA.

AIDS Read. 2003 Oct;13(10):459, 463-4, 468-9, 479. Review. No abstract available.

PMID:
14596223
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk